Saturday 17 October 2026
Export PBM’s income statement to Excel — free account
Psyence Biomedical Ltd.
In the quarter to September 2025, EPS was flat and free cash flow fell 707.2%, each against the same quarter a year earlier.
4.22
0.10
−2.31%
Follow PBM
Psyence Biomedical Ltd. (PBM) P/E ratio
As of 16 October 2026, Psyence Biomedical Ltd. (PBM) trades at a P/E ratio of 0.2×. Over the past ten years it has ranged from 0.0× (September 2024) to 2,929,688× (September 2023); the current reading is higher than 31% of that period. That is below the Biotechnology industry median of 8.5× and below the Healthcare sector median of 23.0×.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|
Against its own ten years
Low 0.0×
High 2,929,688×
Ten-year median
7.5×
Current reading's percentile
13
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| DYAI Dyadic International Inc. compare | n/m |
| MRKR MARKER THERAPEUTICS, INC. compare | n/m |
| TCRX TScan Therapeutics, Inc. compare | n/m |
| ACGN Aceragen, Inc. compare | n/m |
| AKTX Akari Therapeutics PLC compare | n/m |
| ANEB Anebulo Pharmaceuticals, Inc. compare | n/m |
| VAXX Vaxxinity, Inc. compare | n/m |
| PBM Psyence Biomedical Ltd. | 0.2× |
| RADX Radiopharm Theranostics Limited - Sponsored ADR compare | — |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)